Essendi: A New Identity to Foster Responsible Leadership in European Hospitality
28.4.2025 18:30:00 CEST | Business Wire | Press Release
AccorInvest is changing its name and becoming Essendi. This change completes the transformation initiated in 2020 to make Essendi the European leader in responsible hospitality. This new identity embodies the group's ambition: to actively contribute to a more sustainable and higher-performing hotel industry.
Since 2020, Essendi has embarked on an ambitious transformation, aiming to consolidate its leadership in Europe, strengthen its overall performance and integrate ESG criteria at the heart of its strategy.
The group has refocused its portfolio on the most profitable assets in Europe, in the economy and mid-range segments, while optimizing the value of its hotels through dynamic asset management. The value of its portfolio was assessed at €7.8 billion as of December 31, 2024.
This strategy, combined with a hybrid economic model, combining operational and real estate performance, enabled Essendi to achieve record results in 2024: revenue of €4.0 billion (+3.1% like-for-like vs. 2023) and EBITDA of €656 million (+6.1% like-for-like vs. 2023).
Essendi has also strengthened its financial structure by reducing its debt and diversifying its financing, notably through the success of two bond issues in 2024.
Its ESG roadmap is ambitious: a 50% reduction in GHG emissions by 2030, carbon neutrality by 2050, 100% of hotels certified Green Key and 80% of the value of its real estate assets certified BREEAM in Use by 2026.
Essendi is now adopting a strong identity, faithful to its history, and resolutely focused on the future.
- An ambition: to promote positive hospitality.
- A mission: to reveal the potential of each location, serving people and the community.
- Values inspired by the group's hotel DNA:
- Care: sincere attention to people.
- Dare: the audacity to innovate with creativity, commitment and responsibility.
- Empower: the trust given to teams to act and take initiatives for the benefit of the collective.
Gilles Clavié, CEO of Essendi, comments:
“This change of identity completes our transformation and opens a new chapter in our history. The work accomplished by our teams in recent years has paid off: we have strengthened our leadership in Europe, optimized our portfolio, improved our profitability, and consolidated our financial structure.
Beyond these performances, we are proud to position ourselves as a pioneer in sustainable hospitality. Essendi is today a solid, agile, and forward-looking group, ready to seize sustainable growth opportunities in the sector and champion the voice of positive hospitality.”
ABOUT ESSENDI
At Essendi, we do more than operate hotels: we create the dynamics that make them thrive. As a European leader in the economy and midscale segments, we invest and operate with a single ambition: to transform each asset into a sustainable, vibrant, and meaningful place. We combine asset management and operational excellence to unlock the unique potential of every hotel.
Present in 24 countries with 20,000 employees, we operate 576 hotels under internationally renowned brands such as ibis, Novotel, and Mercure, etc.
Wherever we are, we are committed to fostering positive hospitality, acting for the benefit of our business, our teams, and the world around us.
Learn more at Essendi.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250428498255/en/
Contacts
Primatice Conseil :
Thomas de Climens – thomasdeclimens@primatice.com / +33 6 78 12 97 95
Armand Rigaudy – armandrigaudy@primatice.com / +33 7 88 96 41 84
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom